Harrow (HROW) saw its shares surge in the last session with trading volume being higher than average. The latest trend in ...

Fintel reports that on July 11, 2025, Cantor Fitzgerald initiated coverage of Harrow (NasdaqGM:HROW) with a Overweight ...

Harrow, Inc. (NASDAQ:HROW) is one of the 13 Best Pharma Stocks to Buy According to Wall Street Analysts. On June 10, William ...

Harrow (NASDAQ:HROW) stock gains as Cantor Fitzgerald gives an Overweight rating for the company, citing a conservative outlook. Read more here.

Is HROW a good stock to buy now? Harrow Health, Inc. (NASDAQ: HROW) investors should be aware of an increase in activity from the world's largest hedge funds lately.

Harrow's CEO Mark Baum transforms a struggling company into a leader in ophthalmic drugs, with growth in branded products & regulatory risk mitigation. Read more here.

Wasatch Global Investors, an asset management company, released its “Wasatch Micro Cap Value Strategy” fourth-quarter 2023 investor letter. A copy of the same can be downloaded here.

Harrow (HROW) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Moreover, HROW is currently trading at 98.4% of its 52-week High-Low Range, hinting that it can be on the verge of a breakout.